By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
    Health
    Healthcare organizations are operating on slimmer profit margins than ever. One report in August showed that they are even lower than the beginning of the…
    Show More
    Top News
    bowl of vegetable salad
    Raw Foods: benefits and harms
    November 9, 2021
    pros and cons of the keto diet
    Read This Before You Follow the Keto Diet
    May 18, 2022
    spinal cord injuries
    4 Potential Causes of Spinal Cord Injuries (and How to Seek Compensation)
    May 25, 2022
    Latest News
    7 Most Common Healthcare Accreditation Programs: Which Should You Use?
    August 20, 2025
    Hospital Pest Control and the Fight Against Superbugs
    August 20, 2025
    Hygiene Beyond The Clinic: Attention To Overlooked Non-Clinical Spaces
    August 13, 2025
    5 Steps to a Promising Career as a Healthcare Administrator
    August 3, 2025
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
    Policy and Law
    Get the latest updates about Insurance policies and Laws in the Healthcare industry for different geographical locations.
    Show More
    Top News
    TBI: Some Surprising Statistics
    February 9, 2016
    Your Keys to Safer, Even More Secure Healthcare Cloud Services
    January 13, 2015
    4 Career Options in Healthcare Industry that Combine Big Data & Healthcare
    February 5, 2021
    Latest News
    How Social Security Disability Shapes Access to Care and Everyday Health
    August 22, 2025
    How a DUI Lawyer Can Help When Your Future Health Feels Uncertain
    August 22, 2025
    How One Fall Can Lead to a Long Road of Medical Complications
    August 22, 2025
    How IT and Marketing Teams Can Collaborate to Protect Patient Trust
    July 17, 2025
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Neuro Drug Developer iPierian Nets $30M
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > Finance > Neuro Drug Developer iPierian Nets $30M
BusinessFinanceMedical InnovationsSpecialties

Neuro Drug Developer iPierian Nets $30M

Deanna Pogorelc
Deanna Pogorelc
Share
4 Min Read
SHARE

iPierian drug developerOriginally published on MedCityNews.com. 

iPierian drug developerOriginally published on MedCityNews.com. 

Rather than leveraging stem cells for therapeutic use, iPierian Inc. has been using them to create disease models with which it can screen and develop new drugs. Now, with $30 million it’s just collected from investors, iPierian Inc. plans to split two distinct R&D programs that have emerged from those techniques into different companies.

Some of the investment money will continue to fund iPierian’s drug development efforts in neurodegenerative disease. The other portion of it goes toward a Series A for a new spinout called True North Therapeutics. The company declined to specify how the funding was divided.

More Read

How To Launch A Maternity Center In The USA
When Patients Leave: Why They Fire the Doctor
How to Get Good Sleep Hygiene and Why You Need It
What Developers Need to Know About HIPAA Compliance in Wearable Tech
Mobile App to Find Cheapest Drugs

“Given recent positive developments with promising drug candidates, we believe that creating two companies, iPierian and True North, opens up a wider range of possibilities for partnering discussions, allows each company to explore new indications and pipeline opportunities, and optimizes the value to shareholders and patients with the assets built through the scientific legacy of iPierian,” said Jim Scopa, managing director at MPM Capital, in a statement.

MPM Capital co-led the round along with GlaxoSmithKline’s venture capital arm, SR One, and Kleiner Perkins Caufield & Byers. Existing investors like Biogen Idec and Google Ventures also participated, iPierian said.

Since its inception in 2008, the South San Francisco company has been working with a drug discovery platform based on a novel cell regeneration technique. Developed by Nobel Prize winner Shinya Yamanaka of Kyoto University, the techniques allow scientists to convert adult stem cells back into ones that behave like embryotic cells in their ability to be coaxed into a variety of different cell types.

That platform has been used to grow diseases in a dish,” as CEO Nancy Stagliano described in an interview last year, to allow researchers to develop a better understanding of how certain drugs would behave in humans. One of the R&D programs it has yielded targets the treatment of neurodegenerative diseases characterized by tangles of Tau protein, including Alzheimer’s disease. The other targets the classical complement pathway to treat autoantibody-driven rare diseases.

True North Therapeutics was spun off to continue development of the latter program and its lead candidate, TNT009, a monoclonal antibody the company says selectively inhibits a target of the classical complement pathway. The complement system is a part of the immune system that helps the body clear pathogens from an organism. True North says it’s developing drugs for rare diseases in the hematological, renal and neurological therapeutic areas, but a company representative declined to be more specific. With the Series A funding, the company hopes to file an IND within the next 12 to 18 months.

Meanwhile, iPierian will continue working on IPN007, its lead drug candidate for the treatment of tauopathies, with plans to file an IND application in 2014. Following the failure of a group of drugs that went after a different protein, beta amyloid, in clinical trials, the next wave of clinical trials for Alzheimer’s seems to include more products focused on the tau hypothesis. TauRx Pharmaceuticals, for example, is running two late-stage clinical trials for a drug designed to dissolve tangles of tau in the brain. Eli Lilly also recently acquired rights to develop a diagnostic agent to detect tau.

Stagliano, former CEO of CytomX Therapeutics, will continue to head iPierian and will also serve as CEO of True North Therapeutics.

TAGGED:health start-ups!rare diseasestem cells
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

engineer fitting prosthetic arm
How Social Security Disability Shapes Access to Care and Everyday Health
Health care
August 20, 2025
a woman explaining the document
How a DUI Lawyer Can Help When Your Future Health Feels Uncertain
Public Health
August 20, 2025
physiotherapist at work
How One Fall Can Lead to a Long Road of Medical Complications
Health care
August 20, 2025
Common Healthcare Accreditation Programs
7 Most Common Healthcare Accreditation Programs: Which Should You Use?
Health News
August 20, 2025

You Might also Like

workout supplements
FitnessSpecialties

What Health Supplements Actually Work for Your Workout?

April 5, 2021
Preparing for an Accountable Care Organization (ACO) Conversion
BusinesseHealthFinanceHealth ReformPublic Health

Factors Influencing ACO Expansion

April 30, 2014
laser skin therapy is great for creating a more youthful appearance
SkinSpecialties

How Laser Skin Rejuvenation Can Help You Look Younger

August 2, 2022

Increasing Hospital Risks

March 18, 2011
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?